Peter Attia says BPC-157 has patents despite “natural peptides” argument

Peter Attia argues claims that pharmaceutical firms avoid peptides because “natural” molecules cannot be patented are only partly true. He says companies can patent modifications, delivery systems, manufacturing processes and dosing regimens, and adds BPC-157 has patents covering salts and production methods.